DIANE OSBORN: Open Payments
NPI 1205039641 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 8 payments from 5 companies in 2025. Trend: 2023 $13 · 2024 $315 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 2 | $279 |
| Novo Nordisk Inc | 2 | $109 |
| Madrigal Pharmaceuticals | 1 | $83 |
| Esperion Therapeutics, Inc. | 2 | $76 |
| Novartis Pharmaceuticals Corporation | 1 | $47 |
Products named: REPATHA, REZDIFFRA, NEXLETOL, LEQVIO.
Industry payments across OR — which companies pay providers there.
